|Day Low/High||87.79 / 89.27|
|52 Wk Low/High||62.66 / 91.99|
China, and Fed rate hike uncertainty, continue to drive volatility.
The next couple of sessions offer an opportunity to nibble at four names with lower entry points.
Have your shopping list of stocks handy in case markets tank again.
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).
For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.
These stocks will be up so high today, that many fans will say "no thanks."
This market is almost entirely special situation.
Duke Energy's recent increase puts its payout at the high end of the industry range.
The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.
The ABBV chart looks constructive, with solid volume and bullish indicators.
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.
With a weak dollar, calm oil and tame rates, we're doing fine.
Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Drug makers, Apple and other tech stocks among reasonable bargains.